Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €47.31 EUR
Change Today +1.45 / 3.16%
Volume 0.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€46.28
Previous Close
€45.86
Day High
€47.59
Day Low
€45.89
52 Week High
08/5/15 - €51.83
52 Week Low
10/15/14 - €26.07
Market Cap
2.3B
Average Volume 10 Days
18.4
EPS TTM
--
Shares Outstanding
48.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product is Maximum Access Surgery (MAS), a minimally-disruptive surgical platform that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing process consist of Osteocel Plus and Osteocel Pro allograft (donated human tissue), which are cellular matrix products containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during non-spine. The company sells its products through independent sales agencies, directly-employed sales shareowners to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,500 Employees
Last Reported Date: 02/25/15
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

President and Chief Operating Officer
Total Annual Compensation: $545.7K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $380.5K
President of U.S. Commercial
Total Annual Compensation: $375.0K
Executive Vice President of International and...
Total Annual Compensation: $454.1K
Consultant
Total Annual Compensation: $900.0K
Compensation as of Fiscal Year 2014.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. to Expand Manufacturing Facility

NuVasive, Inc. announced that it intends to expand its manufacturing capabilities to meet growing demand for NuVasive's innovative spine technology and is actively exploring locations to build-out a new medical device facility for its spinal implant and instrument manufacturing. This new facility, which would extend the company's existing manufacturing capabilities, will support the company's efforts to increase the amount of products it internally manufactures, and enhance its focus on operational excellence and efforts to drive accelerated operating margin expansion. The build-out and operation of the proposed 130,000-square-foot facility is expected to create hundreds of new jobs, employing more than 300 people on a permanent basis in the disciplines of manufacturing and quality engineers, tool makers, machinists and manufacturing technicians. The new planned facility is expected to house approximately 100 computer numerical control (CNC) machine tools, and inspection equipment, as well as clean-room operations. The company has begun an outreach process in targeted locations to gauge local officials interest in supporting the company's site selection. The company expects to make a decision on the qualifying site by the end of 2015, with the objective of beginning manufacturing at the new facility by year-end 2016.

NuVasive, Inc. Appoints Johnson Lai Chief Information Officer, Effective August 31, 2015

NuVasive, Inc. announced that Johnson Lai has been appointed Chief Information Officer, effective August 31, 2015. In this role, Mr. Lai will be responsible for advancing the Company's information technology systems, processes and procedures into a competitive advantage. Bringing his extensive global IT leadership and medical technology experience to this newly created role, Johnson will help to execute strategic goals, integrate systems and scale business to deliver an outstanding customer experience that differentiates us in the market. Mr. Lai has more than 20 years of IT leadership experience and brings to the role extensive expertise in advancement of enterprise IT initiatives. Most recently, he was Vice President of IT at Thermo Fisher Scientific where he was responsible for providing the IT leadership to the Laboratory Products business group, as well as being an executive member of the integration management team that governed the integration of Life Technologies into Thermo Fisher Scientific. In that capacity, Mr. Lai was responsible for driving processes that created a combined IT vision and successfully executing global programs that achieved the targeted revenue and cost synergy objectives.

NuVasive Reaches Definitive Settlement with U.S. Department of Justice

NuVasive reached a definitive settlement with the U.S. Department of Justice (DOJ) related to the subpoena issued to the company by the Office of Inspector General of the Department of Health and Human Services (OIG) in 2013. Under the terms of the settlement agreement, NuVasive admits to no wrongdoing, but will pay $13.5 million, plus fees and accrued interest.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €47.31 EUR +1.45

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Globus Medical Inc $24.75 USD -0.19
ICU Medical Inc $113.92 USD +0.47
Integra LifeSciences Holdings Corp $60.79 USD +0.25
Masimo Corp $41.51 USD -0.63
Thoratec Corp $62.59 USD +0.20
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings 55.9x
Price/Sales 3.3x
Price/Book 3.9x
Price/Cash Flow 44.2x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.